Rolling the dice on a new treatment method

Awakn Life Sciences Initiates the First Ketamine Treatment Study for Gambling Addiction Led by Professor Celia Morgan

Psilocybin isn’t the only psychedelic that’s being studied for addiction treatment!

Awakn Life Sciences (AWKN) has received approval for the first-ever study on ketamine in gambling addiction –  a disorder that affects 10 million people in the US alone, yet has no licensed pharmacological treatment.

The company will use ketamine-assisted psychotherapy to tackle the urge to gamble as well as superstitious thinking that’s at the root of the addition.

Awakn is also investigating the effects of ketamine and MDMA in treating alcohol use disorder (AUD).

psilera

Psilera Initiates Landmark Preclinical Studies with New Psychedelic Derivatives aimed at Reducing Alcohol Consumption

If you developed a drinking problem during the pandemic, you’re not alone. Alcohol use disorder (AUD) affects 283 million people and growing, which is why Psilera Inc. is studying psilocybin’s anti-addictive properties.

The Florida biotech company launched a new preclinical study that will assess up to seven psychedelic-inspired new chemical entities (NCE) on reducing alcohol consumption. The company aims to limit the psychedelic effects of the drugs to potentially allow administration outside of a clinical setting.

PDF of article

Replacing alcohol with mushrooms?

B.More Advances FDA Drug Trials using Psilocybin to Treat Alcoholism

70% of alcoholics relapse within a year of treatment. Could psilocybin change this?

A recent meta-analysis of the top six best-controlled studies found that patients were 59% more likely to abstain from alcohol use after completing psychedelic therapy. Why is it so effective? Essentially, psychedelics stimulate synaptic growth to “rewire” the brain and break bad habits.

A non-profit in New York called B.More is preparing to build on this research in a Phase 2/3 FDA trial, which will study psilocybin’s effect on alcohol use disorder (AUD).

PDF of article

Cybin’s psychedelic drug formualtion will target Alcohol Use Disorder

Cybin Selects Alcohol Use Disorder Indication for Psychedelic Molecule CYB003

Cybin announced that its proprietary new chemical entity (NCE), CYB003, will target Alcohol Use Disorder in response to increased alcohol use during the pandemic. CEO Doug Drysdale is optimistic that CYB003 will provide “a durable respite from alcohol dependence and the potential to overcome this often-crippling disease”.

PDF of article